Jeil Pharm (002620.KS)
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms in the areas of anti-bacteria and anti-fungal, anti-virus, cardiovascular, endocrinology, neurology, gastrointestinal, urology, oncology, anti-histamine, rheumatology, respiratory, otolaryngological, heaptic, laxatives, and purgatives. The company exports its products to approximately 40 countries in the Association of Southeast Asian Nations, Central and South America, Africa, etc. The company was founded in 1959 and is headquartered in Seoul, South Korea.
Company Info
Highlights
₩140.92B
₩576.01B
₩161.82B
₩6,950.00 - ₩11,000.64
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of ₩10,000 in Jeil Pharm, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading data...
Returns By Period
Jeil Pharm (002620.KS) has returned 17.39% so far this year and -3.77% over the past 12 months. Over the last ten years, 002620.KS has returned -7.95% per year, falling short of the S&P 500 benchmark, which averaged 11.51% annually.
002620.KS
- YTD
- 17.39%
- 1M
- 10.47%
- 6M
- 16.20%
- 1Y
- -3.77%
- 3Y*
- -10.98%
- 5Y*
- -13.39%
- 10Y*
- -7.95%
^GSPC (Benchmark)
- YTD
- 7.06%
- 1M
- 5.28%
- 6M
- 5.00%
- 1Y
- 14.38%
- 3Y*
- 16.95%
- 5Y*
- 14.32%
- 10Y*
- 11.51%
Monthly Returns
The table below presents the monthly returns of 002620.KS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
Based on daily data since Dec 1995, the average daily return (also called the expected return) is 0.11%, while the average monthly return is 2.16%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -1.41% | -5.97% | 15.72% | -4.53% | 3.00% | 1.09% | 9.83% | 17.14% | |||||
| 2024 | -10.20% | 1.51% | 1.03% | -2.58% | -3.22% | -3.23% | -5.97% | -5.91% | 1.60% | -2.25% | -2.53% | -7.09% | -33.14% |
| 2023 | -14.68% | -9.59% | -6.65% | -2.07% | 25.97% | -8.11% | -7.32% | -4.38% | -9.43% | -3.87% | 22.68% | -0.67% | -23.24% |
| 2022 | -18.13% | 0.38% | 6.08% | -6.81% | -3.46% | -4.38% | 11.25% | -5.99% | -24.30% | -0.32% | 8.24% | 50.82% | -3.38% |
| 2021 | -9.67% | -2.61% | -4.02% | 37.15% | 0.20% | 3.46% | -16.31% | -6.57% | -8.04% | -4.92% | -13.22% | 6.38% | -24.23% |
| 2020 | -5.59% | -15.26% | -29.04% | 46.11% | 38.30% | -3.33% | 23.87% | 14.56% | -24.11% | 14.78% | 8.80% | -16.08% | 25.13% |
| 2019 | 1.55% | -2.10% | -7.41% | 5.26% | -15.40% | 4.02% | -20.68% | -12.32% | 0.65% | 15.58% | 1.97% | -5.95% | -33.84% |
| 2018 | 5.03% | -15.29% | 0.16% | -4.86% | -6.59% | -3.00% | -12.91% | 4.38% | 26.80% | -38.64% | 60.41% | -17.07% | -27.73% |
| 2017 | -25.65% | 15.50% | -6.35% | 6.01% | -0.29% | 2.84% | -18.01% | -19.10% | 23.46% | 0.75% | -11.01% | -35.82% | |
| 2016 | -0.13% | 15.23% | 20.45% | 56.66% | 25.15% | -4.31% | -28.50% | 33.29% | 9.65% | -35.22% | -15.95% | 42.48% | 110.85% |
| 2015 | -1.85% | 16.94% | 12.07% | 21.36% | 13.61% | 8.07% | -38.55% | -13.73% | -7.27% | 19.61% | 18.03% | 34.67% | 79.14% |
| 2014 | 12.64% | 14.29% | 0.60% | 10.95% | 28.80% | 9.73% | 9.25% | 1.90% | -29.66% | 15.42% | -6.47% | -2.02% | 68.18% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 002620.KS is 37, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Jeil Pharm (002620.KS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Jeil Pharm provided a 0.55% dividend yield over the last twelve months, with an annual payout of ₩50.00 per share. The company has been increasing its dividends for 2 consecutive years.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | ₩50.00 | ₩50.00 | ₩50.00 | ₩50.00 | ₩65.00 | ₩70.00 | ₩70.00 | ₩70.00 | ₩60.00 | ₩239.21 | ₩205.04 | ₩205.04 |
Dividend yield | 0.55% | 0.64% | 0.42% | 0.32% | 0.41% | 0.33% | 0.41% | 0.27% | 0.17% | 0.43% | 0.77% | 1.37% |
Monthly Dividends
The table displays the monthly dividend distributions for Jeil Pharm. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | |||||
| 2024 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩50.00 | ₩50.00 |
| 2023 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩50.00 | ₩50.00 |
| 2022 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩50.00 | ₩50.00 |
| 2021 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩65.00 | ₩65.00 |
| 2020 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩70.00 | ₩70.00 |
| 2019 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩70.00 | ₩70.00 |
| 2018 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩70.00 | ₩70.00 |
| 2017 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩60.00 | ₩60.00 | |
| 2016 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩239.21 | ₩239.21 |
| 2015 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩205.04 | ₩205.04 |
| 2014 | ₩205.04 | ₩205.04 |
Dividend Yield & Payout
Dividend Yield
Jeil Pharm has a dividend yield of 0.54%, which signifies it pays a smaller percentage of its stock price in dividends to its shareholders compared to other companies in the market.
Payout Ratio
Jeil Pharm has a payout ratio of 16.36%, which is below the market average. This means Jeil Pharm returns a smaller proportion of its earnings to shareholders as dividends, suggesting it retains a higher portion for reinvestment, growth, or debt payment.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Jeil Pharm. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Jeil Pharm was 92.34%, occurring on Mar 4, 2025. The portfolio has not yet recovered.
The current Jeil Pharm drawdown is 89.98%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -92.34% | Jun 16, 2016 | 2105 | Mar 4, 2025 | — | — | — |
| -73.96% | Apr 24, 1997 | 255 | May 13, 1998 | 800 | Aug 13, 2001 | 1055 |
| -58.18% | Jul 30, 2007 | 331 | Dec 2, 2008 | 360 | May 10, 2010 | 691 |
| -56.46% | Jul 2, 2015 | 37 | Aug 24, 2015 | 89 | Jan 4, 2016 | 126 |
| -52.89% | Nov 24, 2005 | 173 | Aug 14, 2006 | 199 | Jun 4, 2007 | 372 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Jeil Pharm over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Jeil Pharm, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -97.9%.
Valuation
The Valuation section provides an overview of how Jeil Pharm is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for 002620.KS compared to other companies in the Drug Manufacturers - Specialty & Generic industry. 002620.KS currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 002620.KS relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 002620.KS has a P/S ratio of 0.2. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 002620.KS in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 002620.KS has a P/B value of 0.5. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |